Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 20 - 24 October 2023, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Doi Number: 10.1016/j.annonc.2023.09.2784
- City: Barcelona
- Country: Spain
- Dokuz Eylül University Affiliated: Yes